Introduction
============

Copy number variations (CNVs) are polymorphisms in the number of copies of chromosomal segments (duplications and deletions) ranging from 1 kb to several Mb and have been recognized as a major contributor to human genetic variability. CNVs collectively encompass a larger part of the genome than single-nucleotide polymorphisms (SNPs).^[@bib1],\ [@bib2],\ [@bib3]^ Mutation rates for CNVs are two to four times higher than those of point mutations and affect larger segments of the genome.^[@bib4],\ [@bib5]^ CNVs have been shown to correlate with changes in gene expression levels.^[@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ Changes in copy number (CN) can also lead to the generation of new combinations of exons between different genes, causing protein changes in structure and modified protein activities.^[@bib10],\ [@bib11]^ Therefore, CNVs are likely to be involved in phenotypic variation, including disease susceptibility, especially when they are large and affect multiple genes. CNVs can be either inherited or *de novo*, with the assumption that *de novo* CNVs are more likely to have deleterious effects.^[@bib12]^ CNVs have been linked to several neuropsychiatric disorders including schizophrenia, autism and attention-deficit hyperactivity disorder (ADHD).^[@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^

We investigated whether there is an association between CNVs (*de novo* and inherited) and Attention Problems (AP) in a selected sample of concordant and discordant monozygotic (MZ) twin pairs. The AP scale has been shown to be predictive for ADHD. Children who score low on the AP scale of the Child Behavior Checklist (CBCL) have a non-ADHD diagnosis in 96% of the cases, and children with a high AP score have a positive diagnosis for ADHD in 36% (girls) and 59% (boys) of cases.^[@bib17]^ In addition, the sensitivity and specificity of the measure is increased if longitudinal scores on AP are considered. Heritability estimates for AP and ADHD in children are about 70% and 75%, respectively,^[@bib18],\ [@bib19]^ and ∼75% of the covariance between the AP scale and ADHD has been estimated to be explained by genetic influences.^[@bib20]^ Previous work that included part of the current MZ sample showed structural^[@bib21]^ and functional^[@bib22]^ brain differences in addition to significant behavior differences among the discordant twin pairs.^[@bib23]^

In this study, MZ twins discordant and concordant for AP are examined for the presence of two types of *de novo* CNVs (1) pre-twinning *de novo* CNVs: CNVs that emerged during parental meiosis, and are therefore shared by the MZ twins, but not by the parents (parental genotypes were available for more than half of the subjects) and (2) post-twinning *de novo* CNVs: CNVs that undergo a CN change in mitosis during the development of one of the twins, causing a discordance between the MZ twins. Post-twinning *de novo* mutations could result in a genetic discordance in all tissues (due to a premorula mutation, most likely at the two-cell stage) or somatic mosaicism (due to mutation at the four-cell stage or later).^[@bib24]^ *De novo* CNVs have been demonstrated in MZ twins^[@bib25]^ and are one mechanism by which phenotypic discordance in MZ twins may be explained. Validation of *de novo* CNVs identified through a genome-wide scan is important because of the tendency to discover false positive mutations when using SNP microarray technology.^[@bib26]^ In this study, we employ the use of quantitative PCR (qPCR) to confirm the *de novo* CNVs indentified from the genome-wide scan for CNVs. In addition, the association between the genome-wide CNV burden and AP is investigated for CNVs genome-wide, CNVs overlapping with genes and CNVs outside of genes (for the *de novo* and inherited CNVs pooled together).

Materials and methods
=====================

Subjects
--------

A total of 50 MZ twin pairs were selected from the Netherlands Twin Register (NTR).^[@bib27]^ Selection was based on longitudinal maternal reports from the AP scale of the CBCL.^[@bib28]^ The AP scale has been used to identify children at risk for clinical ADHD and consists of 11 items (eg, 'cannot sit still, restless or hyperactive\', 'cannot concentrate, pay attention for long\', 'impulsive or acts without thinking\', and so on). Normative scores are provided for the AP scale, which allows for determining whether a child is at risk for ADHD based on gender and age-specific *T*-scores.^[@bib23]^ The AP scale was collected at ages 7, 10 and 12 years and eligible twin pairs were selected from a total sample of 3228 MZ twin pairs. A total of 1966 MZ twin pairs (birth cohorts 1986--1994) had measures from at least two time points and an additional 1256 pairs had longitudinal ratings from all three time points. Children were identified as affected if they had a *T-*score \>60 at all available time points and a *T-*score of at least 65 at one or more time points. Children were classified as unaffected if they had a *T-*score of \<55 at all time points. A *T-*score of 65 represents the clinical cut-off for ADHD.^[@bib17]^ The criterion of longitudinal discordance in MZ twins represents a severe selection measure, as only 18 of the 1966 pairs with longitudinal data available meet this criterion. There were 52 concordant high-scoring twin pairs (both twins affected), 962 concordant low-scoring twin pairs (both twins unaffected) and 18 discordant twin pairs (one affected and one unaffected). The twins were only selected on AP and not on the presence or absence of any other disorders. AP was not measured for the parents. DNA samples were available for 50 MZ pairs: 17 concordant-high (6 male and 11 female pairs), 22 concordant-low (8 male and 14 female pairs) and 11 discordant (4 male and 7 female pairs) twin pairs and 36 parent pairs. The study was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Center, Amsterdam, and an Institutional Review Board certified by the US Office of Human Research Protections (IRB number IRB-2991 under Federal-wide Assurance-3703; IRB/institute codes, NTR 03-180).

Genotyping
----------

Twins and their parents provided buccal swabs for DNA extraction. Methods for buccal swab collection, genomic DNA extraction and zygosity testing have been described previously.^[@bib29]^ Genotyping was performed on the Affymetrix Human Genome-Wide SNP 6.0 Array according to the manufacturer\'s protocol (Affymetrix, Santa Clara, CA, USA). This array contains 906 600 SNPs and 940 000 CN probes. Of the CN probes, 800 000 are evenly spaced across the genome and the rest across 3700 known CNV regions. A total of 172 individuals were genotyped (50 MZ twin pairs and 36 parent pairs). Twins were randomly distributed across plates with respect to AP scores and twins from the same twin pair were genotyped on separate plates. Parents were genotyped together, but not on the same plate as their offspring. Quality control (QC) was done according to the protocol and resulted in a total sample size of 153 individuals comprising 45 complete twin pairs (21 concordant low, 10 discordant and 14 concordant high). Of these 45 complete twin pairs, 25 sets had DNA from both parents who passed QC, 4 complete twin pairs had DNA from one parent who passed QC, the unpaired twins had DNA from one parent who passed QC and 1 unpaired twin had DNA from both parents who passed QC. CNVs were called with the Birdsuite^[@bib30]^ and PennCNV^[@bib31]^ algorithms. CN segments were only included in further analyses if the following conditions were met: (1) the CN calls agreed between both algorithms, (2) the overlapping part of the segments from both algorithms was \>100 kb and (3) the segment was not in a centromere. Because calling algorithms can produce artificially split CNV calls, adjacent CNV calls were merged after visual inspection of LogR ratio (LRR) and B-allele frequency (BAF) plots, if the gap in between was ≤50% of the entire length of the newly merged CNV (see [Supplementary Figure 1](#sup1){ref-type="supplementary-material"} for LRR and BAF plots of all these CNVs). The CNV calling and QC procedures are described in more detail in the [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Pre-twinning *de novo* CNV detection
------------------------------------

CN calls from the 25 MZ twin pairs who had both parents who passed QC were examined to detect possible pre-twinning *de novo* CNV events. These segments were identified with a script written in Perl (scripts are available in the [Supplementary Material](#sup1){ref-type="supplementary-material"}), where segments with the same start and end positions between both twins and both parents, as well as overlapping segments, were compared. If the overlapping segments showed the same CN between twins and a discrepancy with the parental CN calls and the overlap was \>100 kb, the overlapping part was included as a *de novo* CNV segment. In order to judge whether a CNV is inherited or *de novo*, allele-specific CN information is needed from the parents. Because allele-specific CN calls were not available, the allele-specific CNs were assumed to be as follows: if CN=2, each allele is assumed to have a CN of 1 (1--1), if CN=3, 1--2 is assumed, if CN=4, 2--2 is assumed, if CN=1, 1--0 is assumed, if CN=0, 0--0 is assumed. If possible *de novo* CNVs were detected, these were tested for confirmation using qPCR (see [Supplementary Information](#sup1){ref-type="supplementary-material"} for more details on the qPCR replication).

Post-twinning *de novo* CNV detection
-------------------------------------

The CN calls, passing the above per sample and per CNV QC thresholds, of the 45 complete MZ twin pairs were analyzed to detect possible post-twinning *de novo* CNV events. These segments were identified with a program written in Perl (scripts are available in the [Supplementary Material](#sup1){ref-type="supplementary-material"}), where segments with the same start and end positions between twins, as well as overlapping segments, were compared. If two overlapping segments showed a different CN between twins and a size \>100 kb, the overlapping part was identified as a *de novo* CNV segment. Putative *de novo* CNVs were tested for confirmation using qPCR (see [Supplementary Information](#sup1){ref-type="supplementary-material"} for more details on the qPCR replication).

Statistical analysis for genome-wide CNV burden and AP
------------------------------------------------------

Genome-wide CNV burden linked to AP was analyzed with permutation tests in Plink^[@bib32]^ in the 45 complete twin pairs and 4 unpaired twins. Phenotypes were not permuted between males, females or related individuals, thereby correcting for sex and twin relations. The amount of CNV events, as well as the average size, was tested for association with AP status. This was done for three groups of CNV events with any deviation from the expected CN (CN=0, 1, 3 or 4): CNVs genome-wide, CNVs that overlap with genes and CNVs that do not. Significant results were followed by *post-hoc* tests, by testing gains (CN=3 or 4), losses (CN=1 or 0), losses of one copy (CN=1), losses of two copies (CN=0), gains of one copy (CN=3) and gains of two copies (CN=4). Inherited as well as *de novo* CNVs were included in the analysis (*de novo* CNVs that were not validated by qPCR were removed from the analysis). For the male participants, the CNs of the X and Y chromosomes were transformed by adding one copy to the observed CN, in order to include the sex chromosomes with the autosomes in the permutation analysis (ie, the expected CN of 1 was turned into a CN of 2, like in the autosomes). This transformation was not applied to the pseudoautosomal regions (PARs), because these already have an expected CN of 2.

Results
=======

*De novo* CNVs
--------------

A total of 26 *de novo* CNV events were identified from the microarray data: 8 pre-twinning and 18 post-twinning CNVs. CNV qPCR targets for 18 regions in the human genome were identified, which would validate all 26 *de novo* CNVs. The primer- and probe-binding sites for qPCR were selectively chosen in regions within the CNV for which (1) there is no polymorphic SNP, (2) there is no homology to other regions in the genome and (3) there are no common repetitive elements. Based on these criteria, primers and probes could only be selected for 11 of the 18 CNV targets, allowing for testing the validity of 17 of the 26 *de novo* CNVs using the qPCR method (3 pre-twinning and 14 post-twinning CNVs).

Of the three possible pre-twinning *de novo* CNVs that could be included in the qPCR replication study, one was validated on chromosome 15q11.2 in a male concordant-unaffected twin pair (see [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, [Figure 1](#fig1){ref-type="fig"} and [Supplementary Figure 2a](#sup1){ref-type="supplementary-material"}). In this pedigree, both the microarray and qPCR data show that both parents have a CN of 2 in this region and that both twins have a CN of 3. Of the 16 putative post-twinning *de novo* CNVs that were included in the qPCR replication study, qPCR experiments validated 1 *de novo* CNV event, a 1.3-Mb deletion in a male concordant-high twin pair, in the higher scoring co-twin (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"}, [Figure 1b](#fig1){ref-type="fig"} and [Supplementary Figure 2b](#sup1){ref-type="supplementary-material"}). In addition, a 116-kb duplication was not validated nor rejected by the qPCR experiments in the affected twin of a male discordant pair (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"}, [Figure 1c](#fig1){ref-type="fig"} and [Supplementary Figure 2c](#sup1){ref-type="supplementary-material"}).

The 1.3-Mb deletion was initially called as two separate CNVs of 848 and 334 kb by Birdsuite and PennCNV. The qPCR targets were designed for both these regions and the gap in between. All the three qPCR experiments resulted in a deletion for the oldest twin, and a CN of 2 for the youngest, confirming that this is indeed one large deletion that was artificially split by the calling algorithms.

Interestingly, qPCR was not able to reject or validate the microarray-supported hypothesis of a 116-kb *de novo* CNV duplication in the affected twin of a discordant pair on 17p13.2. Despite both the calling algorithms supporting a duplication in this region, the LRR and BAF plots ([Figure 1c](#fig1){ref-type="fig"}) were visually ambiguous, so it was decided to add a second qPCR target to this region 30 kb downstream. The qPCR experiments did not unequivocally validate or refute the presence of a duplication in this region ([Supplementary Figure 2c](#sup1){ref-type="supplementary-material"}). The experiment was repeated three different times for each target assay, with four sample replicates in each experiment. In each instance, the calculated CN for the affected twin was greater than that of unaffected twin (2.34 *vs* 1.91 and 2.40 *vs* 1.97 for the chr17:5921845 and chr17:5951803 targets, respectively).

Genes located within each of the *de novo* CNV regions are summarized in [Table 1](#tbl1){ref-type="table"}. [Figure 1](#fig1){ref-type="fig"} shows the LRR and BAF plots and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"} displays the qPCR replication data of the *de novo* CNV regions. In addition, [Supplementary Figure 3](#sup1){ref-type="supplementary-material"} places each of these *de novo* CNVs in a more global context by showing all of the cataloged structural variations from the Database of Genomic Variations (DGV).

Genome-wide CNV burden and AP
-----------------------------

There was a nominally significant association with AP and the average size of CNVs within genes, where the affected individuals had larger CNV events than the unaffected group (\>120 kb more on average, *P*=0.00830, cf. a level of 0.00833 (=0.05/6) maintains a family-wise type-I error of 0.05, [Table 2](#tbl2){ref-type="table"}). The *post-hoc* tests showed that each type of CNV showed the same trend (a larger average CNV size in the affected group, [Table 3](#tbl3){ref-type="table"}), except for the CNVs with deletions of two copies (CN=0), which was the least common type, occurring only seven times (five events in affected individuals and two events in unaffected individuals). None of these types showed a significant signal, suggesting that the significant effect of burden is due to the combined effect of both losses and gains. The average size of the CNVs did not differ significantly between affected and unaffected individuals for the regions outside of genes. The number of CNVs also did not show significant differences, both within and outside of genes.

Discussion
==========

This study investigated the importance of the number and size of CNVs for AP in 'identical\' twins. The presence of *de novo* CNV mutations and effects of genome-wide CNV burden were examined.

The pre-twinning *de novo* CNVs were examined for a subset of the sample (25 twin pairs) that had genomic DNA from both parents available and who passed QC. One pre-twinning *de novo* CNV mutation was detected that resulted in both MZ twins having a duplication (CN=3) on chromosome 15q11.2. This region contains the gene *HERC2P3*, which is expressed in the human brain ([Table 1](#tbl1){ref-type="table"}). However, both individuals in this twin set scored in the normal range for AP. We assume this to be a *de novo* pre-twinning CNV event, but we recognize the possibility of a rare condition that one of the parents carries two copies for one allele and zero copies on the other allele, in which case this would not be a *de novo* CNV event.

A post-twinning *de novo* deletion of ∼1.3 Mb on 4q35.2 was confirmed with three qPCR experiments in a concordant-affected twin pair. The twin with the deletion had a higher AP score, 20% lower birth weight than the co-twin, scored in the clinical range for the DSM-oriented CBCL scale for conduct problems and performed worse at school according to longitudinal parental and teacher reports. The 4q35.2 subtelomeric deletions found in this twin have been suggested to contribute to co-morbid psychiatric illness and mental retardation.^[@bib33]^ The deletion contains the *FRG1* gene, which is expressed in the human brain. In addition, chromosome 4q35 contains a polymorphic D4Z4 macrosatellite repeat, consisting of 10--100 tandem 3.3-kb D4Z4 repeats. An identical copy of the *DUX4* gene (double homeobox) is located in each of the 3.3-kb repeat elements. Contractions in this polymorphic region have been implicated in facioscapulohumeral muscular dystrophy (FSHD).^[@bib34]^ The *DUX4* protein has been shown to function as a transcriptional activator of the paired-like homeodomain transcription factor 1 (PITX1),^[@bib35]^ which is expressed in the pituitary gland and brain. *DUX4* is a nuclear protein also capable of acting as a pro-apoptotic protein, inducing cell death through caspase 3/7 activity when overexpressed.^[@bib36]^ Although *FRG1* and *DUX4* have been highly implicated in the pathophysiology of FSHD, our findings and the molecular mechanisms of these proteins make them possible targets for follow-up study on how they may have an impact on the developing brain.

The microarray supported hypothesis of a 116-kb duplication on 17p13.2 in the affected twin of a discordant pair could not be validated or rejected using qPCR ([Supplementary Figure 2c](#sup1){ref-type="supplementary-material"}). The algorithm for predicting CN is based on the delta C~T~ of the reference target (in this case RNaseP) to the CNV target of interest. Although experimental variation can affect the calculated CN of the genomic DNA in a qPCR experiment (eg, technical reproducibility, genomic DNA quality, and so on),^[@bib37],\ [@bib38]^ in all instances (12 replicates for two assay targets) the affected twin had a larger calculated CN for this region of the genome. Considering that the genomic DNA was normalized and the fact that these samples are MZ twins makes interpretation of the data difficult. We hypothesize that the duplication in 17p13.2 is a somatic mutation resulting in mosaicism of the affected twin. Somatic mosaicism is generally defined as the presence of genetically distinct populations of cells for a given tissue in the same organism. It has been suggested that somatic mosaicism in pathogenic genes may be relatively common.^[@bib25]^ We cannot conclusively determine this hypothesis, but it was only possible to detect/suspect this by examining MZ twin pairs. Regions in 17p13.2 have been associated with autism spectrum disorder.^[@bib39],\ [@bib40],\ [@bib41]^ The *WSCD1* gene from the duplication in 17p13.2 in the affected twin of the discordant pair is expressed in the brain and is involved in the phospholipid bilayer of the membrane ([Table 1](#tbl1){ref-type="table"}), which has been suggested to have a major role in the high degree of comorbidity between ADHD, dyspraxia and autism spectrum disorders,^[@bib42]^ which have all been reported by the parents and teachers of the carrier of the putative *de novo* duplication. The unaffected co-twin had an above-average IQ and had no health or other problems reported.

Each of the *de novo* CNVs identified in this study has been compared with the catalog of structural variants from the DGV ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). There have been several duplications and deletions reported for the pre-twinning *de novo* CNV on 15q11.2 and the post-twinning deletion on 4q35.2. Interestingly, a slightly larger deletion of 4q35.2 was identified from the Vrije University Hospital clinical database in a child with autism, ADHD and developmental delay without dysmorphism (Petra Zwijnenburg, personal communication). There have not been any duplications reported in the Database for Genomic Variation for the putative *de novo* CNV in the affected twin of a discordant pair on 17p13.2.

The CNVs that were not identified as *de novo* were assumed to be inherited and were included with the *de novo* CNVs in the genome-wide CNV burden association analysis. The association analysis of genome-wide CNV burden and AP showed that CNVs that overlap with genes were larger in size in affected than in unaffected subjects (*P*=0.008). Deletions and duplications showed the same trend, but no significant signals, indicating that both contributed to the main effect. The CNVs that were larger in subjects with high AP scores were scattered across the genome. This suggests that AP might be influenced by many CNVs with small effects, which has been recently revealed to be the case for SNP effects on complex traits as well.^[@bib43]^ Because the majority of human genes are expressed in the cortex,^[@bib44]^ randomly located CNVs affecting genes are likely to have an effect on highly heritable cognitive traits, such as AP. An alternative hypothesis is that neuropsychiatric disorders are caused by rare and highly penetrant CNVs, which often disrupt the balance of dosage-sensitive genes.^[@bib13],\ [@bib45],\ [@bib46]^ Studying the genes affected by this disruption may provide important insights into the susceptibility of disease.

Rare events, such as *de novo* CNVs, are hard to detect when the tools used to measure them are relatively noisy, as is the case with CNV signals from microarray chips that are currently available. In this study, this could be especially problematic when trying to detect post-twinning *de novo* CNVs by comparing twin pairs that were genotyped on separate plates. Stringent QC procedures might not be enough to distinguish real signal from noise, which made replication with qPCR a necessary step to validate the presence of these apparent mutations. In order to accurately detect *de novo* CNVs, it is important to confirm the mutation using a molecular assay more sensitive to CN alterations than the microarrays used to initially screen for them. qPCR has been shown to be highly effective in the validation of CNVs from microarray data.^[@bib26],\ [@bib47],\ [@bib48]^ The outcome of this study shows that even when only considering large CNVs (\>100 kb), there can still be a substantial amount of false positives among the few CN differences between the MZ twins, reflecting the difficulty in measuring CNVs accurately. We excluded the source DNA (buccal-derived) as a major factor. In a different sample of twin families in which blood- and buccal-derived DNAs were collected, we have shown that the CNV calls between blood and buccal sources did not show a greater discordance than those from the same source (eg, both samples from blood), indicating that buccal-derived DNA is suitable for the microarray chip used in the present study (Paul Scheet and Erik A Ehli *et al*, unpublished data). The validated *de novo* CNV, however, confirms that MZ twins are not always 100% genetically identical and that these differences are detectable. An important question remains: how common are these post-twinning *de novo* mutations? To answer this question in more detail, high-throughput CNV-calling methods are needed with higher resolutions and accuracy than the microarray chips currently available. Most heritability studies rely on the assumption that MZ twins are 100% identical.^[@bib49],\ [@bib50]^ Our study largely supports this assumption, but also suggests that the rare post-twinning *de novo* events may lead to phenotypic discrepancies. As a result, the classical twin design may slightly underestimate the genetic effects of a trait. If CNV discordance between MZ twins contributes to phenotypic discordance, the CNV effect on the phenotype would be inadvertently attributed to unique environmental effects in a classical twin study design.

In conclusion, this study found that CNVs that overlap with genes tend to be larger in individuals that consistently score high on AP and who may also have associated elevations in other behavioral problems. Also, two *de novo* CNVs were detected: a pre-twinning duplication and a post-twinning deletion that resulted in a discordance in CN between the MZ twins. Replication studies with larger sample sizes are needed to validate the effect of the size of CNVs on AP and to investigate the effects of the regions where the *de novo* CNVs were found.
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![The pre- and post-twinning *de novo* CNVs. Each plot shows LRR (vertical bars) and BAF (solid points). The LRR and BAF are shown in color in the region of the CNV (red and blue, respectively) and in black in the flanking regions. The actual deletion/duplication is highlighted by a gray rectangle, whereas a CN call of 2 is highlighted by a dashed rectangle. (**a**) Depicts the region of the pre-twinning *de novo* duplication in family 34 for both parents and both twins (both unaffected for AP). The duplication is mainly characterized by an increase in LRR in the twins compared with the parents. The clustering of BAF does not show striking differences between the twins and the parents, most likely because there are relatively few SNP probes in this region (CN probes do not have BAF values). (**b**) Shows the region of the post-twinning deletion in family 5 for both twins (both affected with AP). The deletion is characterized by a decrease in LRR and an altered clustering of BAF, only seen in twin 1 (the oldest twin). (**c**) shows the region of the possible post-twinning duplication in family 33 for both twins (discordant), where twin 2 is affected with AP. Although both calling algorithms called a *de novo* duplication, the LRR and BAF values do not show striking differences when inspected visually, which is why extra qPCR experiments were conducted for this region.](ejhg201249f1){#fig1}

###### Genes within each confirmed *de novo* CNV region. Genes that are in the RefSeq database http://www.ncbi.nlm.nih.gov/gene as well as in the Ensembl database http://www.ensembl.org are reported

  *Gene ID*                          *Description*                                                                              *Tissue expressed (transcripts per million)* [a](#t1-fn2){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                               *Gene ontology (functioning of gene products)* [b](#t1-fn3){ref-type="fn"}
  ---------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *chr15: 18 728 578--19 399 146*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ** **HERC2P3                       Hect domain and RLD 2 pseudogene 3, non-coding RNA                                         Brain (69); Thyroid (42); Uterus (38); Thymus (36); Testis (24); Pharynx (24); Mammary Gland (13); Stomach (10); Placenta (10); Eye (9); Blood (8); Connective Tissue (6); Prostate (5); Embryonic Tissue (4); Intestine (4); Kidney (4); Liver (4); Skin (4)                                                                                                                                                                                          Molecular functions: metal ion binding; ubiquitin-protein ligase activity.
  *chr4: 189 928 060--191 261 904*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ** **HSP90AA4P                     Heat shock protein 90kDa alpha (cytosolic), class A member 4, pseudogene, non-coding RNA   Ascites (24); Skin (4)                                                                                                                                                                                                                                                                                                                                                                                                                                 Cellular components: cytoplasm.Molecular functions: ATP binding; nucleotide binding; unfolded protein binding.Biological processes: protein folding; response to stress.
  ** **FRG1                          FSHD region gene 1, mRNA                                                                   Bone Marrow (143); Pharynx (72); Pituitary Gland (60); Blood (56); Lymph Node (54); Salivary Gland (49); Ovary (48); Parathyroid (48); Eye (47); Muscle (46); Liver (33); Mammary Gland (32); Stomach (31); Uterus (30); Adrenal Gland (30); Embryonic Tissue (27); Lung (26); Prostate (21); Testis (21); Cervix (20); Connective Tissue (20); Pancreas (18); Kidney (14); Skin (14); Bone (13); Heart (11); Intestine (8); Brain (4); Placenta (3)   Cellular components: cajal body; catalytic step 2 spliceosome; nuclear speck; nucleolus; nucleus.Biological processes: nuclear mRNA splicing, via spliceosome; RNA splicing; rRNA processing.
  ** **TUBB4Q                        Tubulin, beta polypeptide 4, member Q, pseudogene, mRNA                                    Skin (4)                                                                                                                                                                                                                                                                                                                                                                                                                                               Cellular components: cytoplasm; cytoskeleton; microtubule. Molecular functions: GTP binding; GTPase activity; nucleotide-binding; structural molecule activity Biological processes: '*de novo*\' posttranslational protein folding; cellular protein metabolic process; microtubule-based movement; protein folding; protein polymerization.
  ** **FRG2                          FSHD region gene 2, mRNA                                                                   NA                                                                                                                                                                                                                                                                                                                                                                                                                                                     Cellular components: nucleus.
  ** **DUX4 family                   double homeobox 4, mRNA                                                                    NA                                                                                                                                                                                                                                                                                                                                                                                                                                                     Cellular components: nucleus.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Molecular functions: sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity.
  *chr17: 5 864 185--5 980 521*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ** **WSCD1                         WSC domain containing 1, mRNA                                                              Muscle (120); Umbilical Cord (73); Pituitary Gland (60); Eye (56); Testis (48); Brain (45); Kidney (37); Ovary (29); Thyroid (21); Bone Marrow (20); Vascular (19); Embryonic Tissue (18); Spleen (18); Placenta (17); Lung (14); Mouth (14); Bone (13); Connective Tissue (13); Heart (11); Pancreas (9); Blood (8)                                                                                                                                   Cellular components: integral to membrane (ie, penetrating at least one phospholipid bilayer of a membrane); membrane (ie, double layer of lipid molecules that encloses all cells, and many organelles; may be a single or double lipid bilayer; also includes associated proteins)Molecular functions: sulphotransferase activity.

Abbreviations: FSHD, facioscapulohumeral muscular dystrophy; NA, tissue-specific gene expression data not available.

Data from NCBI UniGene http://www.ncbi.nlm.nih.gov/unigene.

Data from the Gene Ontology Project http://www.geneontology.org.

###### Results for permutation tests for the number of CNVs genome-wide and their size *vs* AP

  *CNV events*                                *Mean number of CNVs -- unaffected*   *Mean number of CNVs -- affected*   *Empirical* P*-values (number of CNVs vs AP)*   *Average size of CNVs (kb) -- Unaffected*   *Average size of CNVs (kb) -- Affected*   *Empirical* P*-values (size of CNVs vs AP)*
  ------------------------------------------- ------------------------------------- ----------------------------------- ----------------------------------------------- ------------------------------------------- ----------------------------------------- ---------------------------------------------
  CNVs genome-wide (CN=0, 1, 3 and 4)         4.528                                 3.805                               0.961                                           242.2                                       280.0                                     0.058
  CNVs overlapping genes (CN=0, 1, 3 and 4)   2.566                                 1.854                               0.989                                           266.6                                       388.7                                     0.008
  CNVs outside of genes (CN=0, 1, 3 and 4)    2.094                                 2.000                               0.638                                           210.7                                       197.2                                     0.738

Abbreviations: AP, Attention Problems; CN, copy number; CNV, copy number variation.

###### Results for *post-hoc* permutation tests for the size of different types of CNVs genome-wide *vs* AP

                                 *Average size of CNVs (kb) - unaffected*   *Average size of CNVs (kb) -- affected*   *Empirical* P*-values*
  ------------------------------ ------------------------------------------ ----------------------------------------- ------------------------
  Losses (CN=0 and 1)            269.0                                      330.0                                     0.198
  Deletion: 1 copy (CN=1)        264.1                                      361.8                                     0.099
  Deletion: 2 copies (CN=0)      356.1                                      266.8                                     0.687
  Gains (CN=3 and 4)             330.0                                      434.5                                     0.104
  Duplication: 1 copy (CN=3)     335.5                                      420.6                                     0.149
  Duplication: 2 copies (CN=4)   193.6                                      441.1                                     0.226

Abbreviations: AP, Attention Problems; CN, copy number; CNV, copy number variation.

[^1]: These authors contributed equally to this work.
